DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20195260

Safety and efficacy of palonosetron compared in prevention of postoperative nausea and vomiting in patients undergoing elective major surgery under general anaesthesia

Neha Godre, Mirza Shiraz Baig

Abstract


Background: Post-operative nausea and vomiting continues to be a common side effect of surgery and anaesthesia, affecting the economics of medical care, as well as the degree of patients’ satisfaction, comfort and quality of life.The objective of the present study were to compare the efficacy and safety of palonosetron versus placebo for prophylaxis of early onset (within 24 hours post-surgery) and late onset (24-72 hours post-surgery) post-operative nausea or vomiting in patients undergoing elective major surgery under general anaesthesia.

Methods: A prospective, randomized, parallel group, two arm, double blind placebo controlled trial was conducted on n=100 indoor patients undergoing elective major surgeries were enrolled into the present study.

Results: The patients showing complete response were 32 (64%) in palonosetron group and 19 (38%) in the placebo group (p<0.05) in the 0-24 hour time interval. The patients receiving palonosetron showed higher complete response rates in the 0-24 hour and 0-72 hour time intervals. 42 patients (84%) on palonosetron and 30 (60%) on placebo showed complete control of vomiting in 0-24 hour period. Adverse events related to the drug were reported in 5 patients (10%) in palonosetron group as compared to 3 patients (6%) in placebo group.

Conclusions: A single prophylactic 0.075 mg IV dose of palonosetron effectively reduced the occurrence and severity of nausea and vomiting and delayed the time to emesis and treatment failure in the early as well as the overall postoperative period of 72 hours.


Keywords


Palonosetron, Efficacy and safety, Post-operative nausea and vomiting

Full Text:

PDF

References


Pasricha PJ. Treatment of disorders of bowel motility and water flux; antiemetics; agents used in biliary and pancreatic disease. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006: 983-1008.

Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, et al. Society for ambulatory anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007;105(6):1615-28.

Kovac AL. Prevention and treatment of postoperative nausea and vomiting. In: Donnerer J, ed. Antiemetic Therapy. Basel: Karger; 2003: 121-160.

Stadler M, Bardiau F, Seidel L, Albert A, Boogaerts JG. Difference in Risk Factors for Postoperative Nausea and Vomiting. Anesthesiol. 2003;98(1):46-52.

Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg. 2006;102(6):1884–98.

Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiol. 1992;77(1):162-84.

Donnerer J, Beubler E. 5-HT3 Receptor Antagonists in Antiemetic Therapy. In: Donnerer J, ed. Antiemetic therapy. Basel: Karger; 2003: 22-32.

McQuaid KR. Drugs used in the treatment of gastrointestinal diseases. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic and clinical pharmacology. 11th ed. New Delhi: Tata McGraw-Hill; 2009: 1067-1102.

Palonosetron full prescribing information (label). Available at: drugs@fda.gov.http://www.accessdata. fda.gov/drugsatfda_docs/label/2008/021372s008s010lbl.pdf. Accessed on 10 October 2019.

Muchatuta NA, Paech MJ. Management of postoperative nausea and vomiting: focus on Palonosetron. Ther Clin Risk Manag. 2009;5(1):21-34.

Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008;107(2):469–78.

Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT(3)R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2011;19(6):823-32.

Candiotti KA, Kovac AL, Melson TI, Clerici G, Gan TJ. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg. 2008;107(2):445–51.

Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg. 2008;107(2):439–44.